Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: manny t who wrote (45933)	1/19/2001 5:03:33 PM
From: Brasco One	Respond to of 57584

U.S. judge says Amgen's anemia drug patent infringed BOSTON, Jan 19 (Reuters) - At least one of biotech bellwether Amgen's (NasdaqNM:AMGN - news) patents for its anemia drug Epogen was infringed upon by Transkaryotic Therapies (NasdaqNM:TKTX - news), a relatively tiny Cambridge, Mass.-based company, a federal judge ruled on Friday. U.S. District Judge William Young in a 245-page decision found that Amgen's 422 patent ``is valid, enforceable, and literally infringed.'' Amgen reaped about $1.8 billion in sales in 1999 from Epogen, and worldwide revenues were some $4 billion including sales through Amgen's licensing partner Johnson & Johnson (NYSE:JNJ - news). Transkaryotic, with backing from Franco-German pharmaceutical giant Aventis , had developed an alternative method of developing the drug.